HemoHIM administration significantly enhanced IL-2 (p < 0.001; Fig. 5C) and IFN-γ (p < 0.05; Fig. 5D) production in melanoma-bearing mice treated with cisplatin. The gene discussed is IFNG; the disease is melanoma.